Researchers Discover Important Piece of Genetic Aging Puzzle

Publication
Article
OncologyONCOLOGY Vol 11 No 10
Volume 11
Issue 10

A team of researchers has disrupted the natural progression of division and death in human cells, endowing the cells with an

A team of researchers has disrupted the natural progression of division and death in human cells, endowing the cells with an extended life-span.

Reporting in the journal Science, Brown University researchers describe how they can temporarily thwart the aging process by removing a gene, dubbed p21, from ordinary human cells cultivated in the laboratory. Cells without the gene divide for up to 30 additional generations before dying.

The researchers modified a gene “knock-out” method that is routinely used to genetically engineer mice for scientific research, and used the technology to remove the p21 gene from human cells. The knock-out method described in Science allows for specific changes in manipulating human cells.

“For obvious ethical and medical reasons, we can’t make a knock-out human, and we’re not going to clone a human, so this is as close as we can get,” said John Sedivy, associate professor of molecular biology, cellular biology and biochemistry. Because cancer cells appear to possess an infinite life-span, the finding may offer insight into how human cells become tumor cells, an important step in understanding the cancer process, he said.

Moreover, the finding has broad disease-fighting implications because it allows scientists to study genetically varied human cells without altering human beings to produce such cells.

The research may have important gene therapy implications. “There is no reason we couldn’t take cells from a patient, alter them, and put them back in that patient,” said Sedivy. 

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Related Content